

Clarke, G., Stone, T. W. and Schwarcz, R. (2017) The kynurenine pathway: Towards metabolic equilibrium. *Neuropharmacology*, 112(part B), pp. 235-236. (doi:[10.1016/j.neuropharm.2016.08.029](https://doi.org/10.1016/j.neuropharm.2016.08.029))

This is the author's final accepted version.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/124325/>

Deposited on: 12 October 2016

Editorial for the Special Issue on Kynurenines in Neuropharmacology

Eds. Clarke, G., Stone, T. W., and Schwarcz, R

The Kynurenine Pathway: Towards Metabolic Equilibrium

Clarke, G., Stone, T. W., and Schwarcz, R.

Metabolism of tryptophan along the kynurenine pathway yields multiple metabolites that collectively exhibit both a rich pharmacology and a broad neurobiological significance (Schwarcz *et al.* 2012). This includes not just neurotoxic and neuroprotective metabolites that exert their influence via opposing action at NMDA receptors but also molecules with activity at metabotropic glutamate receptor subtypes, the aryl hydrocarbon receptor and specific G-protein coupled receptors (GPCRs) (Stone *et al.* 2013). Despite the therapeutic possibilities arising from this extensive pharmacological repertoire, kynurenines have struggled to reach a status in the scientific consciousness comparable with other tryptophan metabolites such as serotonin and melatonin. The growing realisation that the sphere of influence of dysregulated metabolism extends to most fundamental aspects of brain function with manifestations possible across the life span has seen this imbalance somewhat rectified. Now that these metabolites are no longer neglected, it is not surprising that altered metabolism along this pathway has been associated with numerous psychiatric and neurological disorders. Indeed, the immunoresponsive and stress-reactive nature of kynurenine pathway enzymes has stimulated biomarker studies and brought into focus a number of appealing therapeutic targets of relevance across a wide swathe of pathologies. The pathway still holds much unlocked potential and although there is now a solid grasp of many of its features and nuances, there remain understudied metabolites and enzymes as well as the capacity for ongoing research to reveal new layers of complexity and provide fresh insights.

This special issue of *Neuropharmacology* is an effort to provide a collection of articles to illustrate the research challenges and opportunities provided by our mounting but still incomplete knowledge of kynurenine pathway metabolism. Schwarcz and Stone (ref) chart the rise of the kynurenines from relative obscurity to their current prominence. This overview

also illuminates the knowledge gaps to be bridged, and the pitfalls and promise inherent in this complex area of research. Clearly, an understanding of kynurenine pathway metabolism is contingent on a solid appreciation of the factors influencing the availability of tryptophan under both normal and pathological conditions (Badawy 2015). Fujigaki and colleagues (Fujigaki *et al.* 2016) further elaborate on the mechanisms that regulate kynurenine enzyme expression and activity with an emphasis on cell-type specific features of the metabolic cascade.

The implications of altered metabolism of tryptophan along the kynurenine pathway are manifold and may manifest across the life span. Notarangelo and Pocivavsek (Notarangelo and Pocivavsek 2016) emphasise the important role of fluctuations in these neuroactive metabolites during critical neurodevelopmental windows, visible particularly in cognitive impairments expressed in adulthood following kynurenic acid modulation during gestation or postnatally. The role of the immune system in activating kynurenine pathway metabolism has implications for numerous disorders, particularly when viewed through the lens of infection-mediated alterations in behaviour and the links between immune system malfunction and psychopathology (Strasser *et al.* 2016). Equally, activation of the kynurenine pathway by glucocorticoids is an important factor for many stress-related disorders (O'Farrell and Harkin 2015). The possibility that kynurenine pathway metabolism could be implicated as a neurobiological factor underpinning suicidality has also received attention (Bryleva and Brundin 2016). It is also important to bear in mind that some kynurenines participate in redox reactions and this may have repercussions for critical biological functions that malfunction in relevant pathologies (Gonzalez Esquivel *et al.* 2016).

As research advances in this area and moves beyond more general concepts of pathway activation, it is clear that certain metabolites of the kynurenine pathway may hold special relevance for specific disorders. For example, much research now associates the accumulation of quinolinic acid with Amyotrophic lateral sclerosis (ALS) (Lee *et al.* 2016). In tandem, information about an expanding range of molecular targets continues to emerge for previously understudied metabolites including cinnabarinic acid as an orthosteric agonist of mGlu4 receptors and the activation of mGlu2 and mGlu3 receptors by xanthurenic acid (Fazio *et al.* 2016). Given the important role of metabotropic glutamate receptors in the CNS as well as in peripheral and non-neural tissues, this is a promising avenue of investigation (for review see: (Julio-Pieper *et al.* 2011)).

These and other developments highlighting the therapeutic potential in targeting kynurenine pathway metabolism have encouraged the extension of research on the kynurenine pathway to other neurological disorders such as multiple sclerosis as well as HIV-associated neurocognitive disorders (Lovelace *et al.* 2016). The CNS impact of parasitic diseases, such as malaria and toxoplasmosis, has also been considered in the context of their impact on kynurenine production (Hunt *et al.* 2016). Finally, Kennedy *et al.* (Kennedy *et al.* 2016) evaluate the emerging research supporting a role for the gut microbiota in the regulation of kynurenine pathway metabolism.

Taken together, the breadth of these topics should make clear our motivation to put the kynurenine pathway under the spotlight in this special issue. The capacity of the kynurenines to surprise us should not be underestimated and we hope that the insights in this compilation of articles provides both stimulus and direction for ongoing research efforts and new researchers in the field. Now that consequences of the dysregulation of kynurenine pathway metabolism is more fully appreciated and as the range of activity of the kynurenines is further teased apart, we can start to envisage the benefits of interventions that move us back towards a metabolic equilibrium.

References

1. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. *Nature reviews Neuroscience*. 2012 Jul;13(7):465-77. PubMed PMID: 22678511. Pubmed Central PMCID: 3681811.
2. Stone TW, Stoy N, Darlington LG. An expanding range of targets for kynurenine metabolites of tryptophan. *Trends in pharmacological sciences*. 2013 Feb;34(2):136-43. PubMed PMID: 23123095.
3. Badawy AA. Tryptophan availability for kynurenine pathway metabolism across the life span: Control mechanisms and focus on aging, exercise, diet and nutritional supplements. *Neuropharmacology*. 2015 Nov 23. PubMed PMID: 26617070.
4. Fujigaki H, Yamamoto Y, Saito K. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences. *Neuropharmacology*. 2016 Jan 6. PubMed PMID: 26767951.
5. Notarangelo FM, Pocivavsek A. Elevated kynurenine pathway metabolism during neurodevelopment: Implications for brain and behavior. *Neuropharmacology*. 2016 Mar 2. PubMed PMID: 26944732.
6. Strasser B, Becker K, Fuchs D, Gostner JM. Kynurenine pathway metabolism and immune activation: Peripheral measurements in psychiatric and co-morbid conditions. *Neuropharmacology*. 2016 Feb 26. PubMed PMID: 26924709.
7. O'Farrell K, Harkin A. Stress-related regulation of the kynurenine pathway: Relevance to neuropsychiatric and degenerative disorders. *Neuropharmacology*. 2015 Dec 12. PubMed PMID: 26690895.

8. Bryleva EY, Brundin L. Kynurenine pathway metabolites and suicidality. *Neuropharmacology*. 2016 Jan 26. PubMed PMID: 26820800.
9. Gonzalez Esquivel D, Ramirez-Ortega D, Pineda B, Castro N, Rios C, Perez de la Cruz V. Kynurenine pathway metabolites and enzymes involved in redox reactions. *Neuropharmacology*. 2016 Mar 9. PubMed PMID: 26970015.
10. Lee JM, Tan V, Lovejoy D, Braidy N, Rowe DB, Brew BJ, et al. Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis. *Neuropharmacology*. 2016 Jun 3. PubMed PMID: 27265569.
11. Fazio F, Lionetto L, Curto M, Iacovelli L, Copeland CS, Neale SA, et al. Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors. *Neuropharmacology*. 2016 Jun 21. PubMed PMID: 27342123.
12. Julio-Pieper M, Flor PJ, Dinan TG, Cryan JF. Exciting times beyond the brain: metabotropic glutamate receptors in peripheral and non-neural tissues. *Pharmacological reviews*. 2011 Mar;63(1):35-58. PubMed PMID: 21228260.
13. Lovelace MD, Varney B, Sundaram G, Lennon MJ, Lim CK, Jacobs K, et al. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. *Neuropharmacology*. 2016 Mar 16. PubMed PMID: 26995730.
14. Hunt NH, Too LK, Khaw LT, Guo J, Hee L, Mitchell AJ, et al. The kynurenine pathway and parasitic infections that affect CNS function. *Neuropharmacology*. 2016 Feb 26. PubMed PMID: 26924710.
15. Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Kynurenine pathway metabolism and the microbiota-gut-brain axis. *Neuropharmacology*. 2016 Jul 5. PubMed PMID: 27392632.